Ceribell is focused on making electroencephalography (EEG), a method of recording electrical activity of the brain, widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. About 25% of the neurological patients and cardiac arrest patients in the ICU have non-convulsive seizures. The company strives to enable earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, which can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.